Blood Pressure Time in Target Range and its Impact on Clinical Outcomes.
Cardiovascular disease
Cardiovascular disease prevention
Cardiovascular outcomes
Hypertension
Time in target range
Time in therapeutic range
Journal
Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
accepted:
28
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
To examine the concept of time in target range for blood pressure (BP) management, exploring its calculation methods, implications for patient outcomes, and potential use in patient care. Recent post-hoc analyses of clinical trials and observational studies highlight the importance of BP time in target range in predicting cardiovascular outcomes. Higher time in target range correlates with reduced risks of major adverse cardiovascular events including heart failure, stroke, myocardial infarction and all-cause mortality. Additionally, longer time in target range decreases the risk of incident atrial fibrillation and risk of developing dementia. BP time in target range is a novel metric offering valuable insights into BP control and its impact on clinical outcomes. Higher time in target range is consistently associated with better cardiovascular outcomes across various patient populations. However, the clinical application of BP time in target range requires further investigation through prospective clinical trials and real-world studies. Integrating wearable devices for continuous BP monitoring could enhance the practical utility of BP time in target range in hypertension management.
Identifiants
pubmed: 39141252
doi: 10.1007/s11886-024-02111-9
pii: 10.1007/s11886-024-02111-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37.
doi: 10.1038/s41581-019-0244-2
pubmed: 32024986
pmcid: 7998524
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–200.
doi: 10.1001/jama.2020.14545
pubmed: 32902588
Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47:1099–102.
doi: 10.1038/s41440-024-01622-w
pubmed: 38443614
Yano Y, Reis JP, Colangelo LA, et al. Association of blood pressure classification in young adults using the 2017 American college of cardiology/American heart association blood pressure guideline with cardiovascular events later in life. JAMA. 2018;320:1774–82.
doi: 10.1001/jama.2018.13551
pubmed: 30398601
pmcid: 6248102
Son JS, Choi S, Kim K, et al. Association of blood pressure classification in Korean young adults according to the 2017 American college of cardiology/American heart association guidelines with subsequent cardiovascular disease events. JAMA. 2018;320:1783–92.
doi: 10.1001/jama.2018.16501
pubmed: 30398603
pmcid: 6248107
A Randomized Trial of Intensive versus Standard Blood-Pressure Control | New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 . Accessed 19 Jun 2024
Wang J, Shi X, Ma C, Zheng H, Xiao J, Bian H, Ma Z, Gong L. Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2017;35:10–7.
doi: 10.1097/HJH.0000000000001159
pubmed: 27906836
Clark D, Nicholls SJ, St John J, Elshazly MB, Ahmed HM, Khraishah H, Nissen SE, Puri R. Visit-to-visit blood pressure variability, coronary atheroma progression, and clinical outcomes. JAMA Cardiol. 2019;4:437–43.
doi: 10.1001/jamacardio.2019.0751
pubmed: 30969323
pmcid: 6537804
Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.
doi: 10.1161/CIRCULATIONAHA.107.750000
pubmed: 18955670
Erkens PMG, ten Cate H, Büller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One. 2012;7:e42269.
doi: 10.1371/journal.pone.0042269
pubmed: 23049730
pmcid: 3458058
Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One. 2017;12:e0188482.
doi: 10.1371/journal.pone.0188482
pubmed: 29155884
pmcid: 5695846
Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15:213–6.
doi: 10.1023/B:THRO.0000011377.78585.63
pubmed: 14739631
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–9.
doi: 10.1055/s-0038-1651587
pubmed: 8470047
Chung S-C, Pujades-Rodriguez M, Duyx B, Denaxas SC, Pasea L, Hingorani A, Timmis A, Williams B, Hemingway H. Time spent at blood pressure target and the risk of death and cardiovascular diseases. PLoS One. 2018;13:e0202359.
doi: 10.1371/journal.pone.0202359
pubmed: 30183734
pmcid: 6124703
Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J Am Heart Assoc. 2017;6:e007131.
doi: 10.1161/JAHA.117.007131
pubmed: 29101118
pmcid: 5721788
Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J Am Coll Cardiol. 2021;77:1290–9.
doi: 10.1016/j.jacc.2021.01.014
pubmed: 33706870
pmcid: 7959178
Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, Dixon DL. Systolic blood pressure time in target range and major adverse kidney and cardiovascular events. Hypertension. 2023;80:305–13.
doi: 10.1161/HYPERTENSIONAHA.122.20141
pubmed: 36254738
Chen K, Wu Z, Shi R, Wang Q, Yuan X, Wu G, Shi G, Li C, Chen T. Longer time in blood pressure target range improves cardiovascular outcomes among patients with type 2 diabetes: a secondary analysis of a randomized clinical trial. Diabetes Res Clin Pract. 2023;198:110600.
doi: 10.1016/j.diabres.2023.110600
pubmed: 36858262
Lin Z, Xiao Z, Chen W, et al. Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study. Eur J Prev Cardiol. 2023;30:969–77.
doi: 10.1093/eurjpc/zwad083
pubmed: 36947144
Chen K, Li C, Cornelius V, et al. Prognostic value of time in blood pressure target range among patients with heart failure. JACC Heart Fail. 2022;10:369–79.
doi: 10.1016/j.jchf.2022.01.010
pubmed: 35654521
Huang R, Lin Y, Liu M, Xiong Z, Zhang S, Zhong X, Ye X, Huang Y, Zhuang X, Liao X. Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2022;11:e022765.
doi: 10.1161/JAHA.121.022765
pubmed: 35289182
pmcid: 9075464
Wang J, Jiang C, Li S, et al. Systolic blood pressure time in target range and incident atrial fibrillation in patients with hypertension: insights from the SPRINT trial. Hypertension. 2023;80:2306–14.
doi: 10.1161/HYPERTENSIONAHA.123.21651
pubmed: 37589154
Mahfoud F, Mancia G, Schmieder RE, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol. 2022;80:1871–80.
doi: 10.1016/j.jacc.2022.08.802
pubmed: 36357087
Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, Bosch J, O’Donnell MJ, Canavan M. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323:1934–44.
doi: 10.1001/jama.2020.4249
pubmed: 32427305
Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43:4980–90.
doi: 10.1093/eurheartj/ehac584
pubmed: 36282295
Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American heart association. Hypertension. 2016;68:e67–94.
doi: 10.1161/HYP.0000000000000053
pubmed: 27977393
Jiang He, Chuansheng Zhao, Shanshan Zhong, et al. Effectiveness of blood pressure-lowering intervention on risk of total dementia among patients with hypertension: a cluster-randomized effectiveness trial. 2023.
van Dalen JW, Brayne C, Crane PK, et al. Association of systolic blood pressure with dementia risk and the role of age, U-shaped associations, and mortality. JAMA Intern Med. 2022;182:142–52.
doi: 10.1001/jamainternmed.2021.7009
pubmed: 34901993
Li S, Jiang C, Wang Y, et al. Systolic blood pressure time in target range and cognitive outcomes: insights from the SPRINT MIND Trial. Hypertension. 2023;80:1628–36.
doi: 10.1161/HYPERTENSIONAHA.122.20711
pubmed: 37165869
Belani S, Wahood W, Hardigan P, Placzek AN, Ely S. Accuracy of detecting atrial fibrillation: a systematic review and meta-analysis of wrist-worn wearable technology. Cureus. 2021;13:e20362.
pubmed: 35036196
pmcid: 8752409
Mannhart D, Lischer M, Knecht S, et al. Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL wearable study. JACC Clin Electrophysiol. 2023;9:232–42.
doi: 10.1016/j.jacep.2022.09.011
pubmed: 36858690
Ford C, Xie CX, Low A, Rajakariar K, Koshy AN, Sajeev JK, Roberts L, Pathik B, Teh AW. Comparison of 2 smart watch algorithms for detection of atrial fibrillation and the benefit of clinician interpretation: SMART WARS study. JACC Clin Electrophysiol. 2022;8:782–91.
doi: 10.1016/j.jacep.2022.02.013
pubmed: 35738855
Beevers G, Lip GY, O’Brien E. ABC of hypertension: blood pressure measurement. Part II-conventional sphygmomanometry: technique of auscultatory blood pressure measurement. BMJ. 2001;322:1043–7.
doi: 10.1136/bmj.322.7293.1043
pubmed: 11325773
pmcid: 1120188
Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American heart association. Hypertension. 2019;73:e35–66.
doi: 10.1161/HYP.0000000000000087
pubmed: 30827125
Kario K. Management of hypertension in the digital era: small wearable monitoring devices for remote blood pressure monitoring. Hypertension. 2020;76:640–50.
doi: 10.1161/HYPERTENSIONAHA.120.14742
pubmed: 32755418
Konstantinidis D, Iliakis P, Tatakis F, Thomopoulos K, Dimitriadis K, Tousoulis D, Tsioufis K. Wearable blood pressure measurement devices and new approaches in hypertension management: the digital era. J Hum Hypertens. 2022;36:945–51.
doi: 10.1038/s41371-022-00675-z
pubmed: 35322181
pmcid: 8942176
Islam SMS, Chow CK, Daryabeygikhotbehsara R, Subedi N, Rawstorn J, Tegegne T, Karmakar C, Siddiqui MU, Lambert G, Maddison R. Wearable cuffless blood pressure monitoring devices: a systematic review and meta-analysis. Eur Heart J Digit Health. 2022;3:323–37.
doi: 10.1093/ehjdh/ztac021
pubmed: 36713001
pmcid: 9708022
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76.
doi: 10.1056/NEJMoa0805017
Jackson MA, Ahmann A, Shah VN. Type 2 diabetes and the use of real-time continuous glucose monitoring. Diabetes Technol Ther. 2021;23:S27–34.
doi: 10.1089/dia.2021.0007
pubmed: 33534631
Seidu S, Kunutsor SK, Ajjan RA, Choudhary P. Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence. Diabetes Care. 2024;47:169–79.
doi: 10.2337/dc23-1520
pubmed: 38117991